Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7470835 | 0.92 | DDR1 (0.49) | ELANECYP4F2CYP4A11F10MEN1 | |
| SCHEMBL29035735 | 0.88 | ALDH1A1 (0.58) | MEN1KMT2AMAPTMRGPRX4TDP1 | |
| SCHEMBL5751056 | 0.88 | CYP4F2 (0.51) | CYP4F2CYP4A11F10MEN1KMT2A | |
| SCHEMBL8810201 | 0.84 | F10 (0.49) | ELANEF10F2MRGPRX4POLB | |
| SCHEMBL2341305 | 0.84 | KAT6A (0.48) | MRGPRX4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL31182094 | 0.84 | POLB (0.51) | ELANEMEN1KMT2AMRGPRX4POLB | |
| SCHEMBL28332878 | 0.84 | F10 (0.53) | CYP4F2CYP4A11F10MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8552872 | 0.83 | F10 (0.48) | ELANEF10F2MRGPRX4POLB | |
| SCHEMBL31618892 | 0.83 | CYP4F2 (0.52) | CYP4F2CYP4A11F10MEN1KMT2A | |
| SCHEMBL27655999 | 0.83 | CYP4F2 (0.52) | CYP4F2CYP4A11F10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063302-A | Metal complex and electroluminescent device containing same | 北京夏禾科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-111018921-B | Metal complex and electroluminescent device containing same | 北京夏禾科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| CN-111285850-A | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-06-16 | — | — | CN | disclosed |
| WO-2020114482-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | 中国科学院上海药物研究所 | 2020-06-11 | — | — | WO | disclosed |
| CN-111018921-A | Metal complex and electroluminescent device containing same | 北京夏禾科技有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2768834-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2768834-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| CN-102725290-B | As the condensed heterocyclic compouds of ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-03-09 | — | — | CN | disclosed |
| US-20140249147-A1 | Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators | GlaxoSmithKline, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249147-A1 | Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators | GlaxoSmithKline, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2768834-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| CN-104011053-A | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2014-08-27 | — | — | CN | disclosed |
| WO-2013059589-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059589-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013004984-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-10 | — | — | WO | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | NIHON NOHYAKU CO., LTD., (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1544202-A1 | NOVEL HERBICIDES, USAGE THEREOF, NOVEL THIENOPYRIMIDINE DERIVATIVES, INTERMEDIATES OF THE SAME, AND PROCESS FOR PRODUCTION THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010402-A1 | Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof | DDT, DPYD, DHODH | ELANE 4800/4885CYP4F2 71/4885CYP4A11 304/4885 |
| US-20140249147-A1 | Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | ELANE 3453/4885CYP4F2 1985/4885CYP4A11 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.